Jackson Park Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Jackson Park Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.12M	Sell	31,000 -8,000	-21%	-$319K	2.09%	27
2016 Q3	$1.79M	Hold	39,000	–	–	2.33%	22
2016 Q2	$1.96M	Hold	39,000	–	–	2.68%	16
2016 Q1	$2.09M	Sell	39,000 -5,000	-11%	-$293K	2.69%	15
2015 Q4	$2.89M	Hold	44,000	–	–	2.98%	19
2015 Q3	$2.48M	Hold	44,000	–	–	2.15%	26
2015 Q2	$2.6M	Sell	44,000 -66,000	-60%	-$4.07M	2.11%	24
2015 Q1	$6.85M	Sell	110,000 -88,000	-44%	-$5.12M	5.87%	2
2014 Q4	$11.4M	Buy	+198,000	New	+$11M	9.07%	1

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Jackson Park Capital's TEVA Position: Q4 2016 in Review

Jackson Park Capital reduced its Teva Pharmaceuticals (TEVA) stake by 21% in Q4 2016, selling an estimated $319K and leaving 31,000 shares worth $1.12M. The position accounts for 2.09% of the portfolio, ranked #27.

Jackson Park Capital first reported a position in TEVA in Q4 2014 and has held it in 9 quarters since. The position peaked at $11.4M in Q4 2014. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Jackson Park Capital held 31,000 shares of Teva Pharmaceuticals worth $1.12M as of Q4 2016.
Jackson Park Capital sold 8,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $319K.
Teva Pharmaceuticals made up 2.09% of Jackson Park Capital's portfolio in Q4 2016, its #27 holding.
Jackson Park Capital first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 9 quarters since.
Jackson Park Capital's Teva Pharmaceuticals position peaked at $11.4M in Q4 2014.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Jackson Park Capital's 13F filing for Q4 2016, filed 1 Feb 2017.